跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML0195

Sigma-Aldrich

米法莫肽

≥98% (HPLC)

别名:

CGP-19835, MTP-PE, MTP-脑磷脂, N-（N-乙酰胞壁酰）-L-丙氨酰-D-α-谷氨酰胺基-N- [(7R)-4-羟基-4-氧化-10-氧代-7- [（1-氧代十六烷基）氧]-3,5,9-三氧-4-磷酸五氯-1-基]-L-丙氨酸酰胺, 胞壁酰三肽磷脂酰乙醇胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C59H109N6O19P
CAS号:
83461-56-7
分子量:
1237.50
UNSPSC代码:
12352200
PubChem化学物质编号:
329825220
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to beige

溶解性

water: 2 mg/mL, clear (warmed)

创始人

Novartis

储存温度

−20°C

SMILES字符串

CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC

InChI

1S/C59H109N6O19P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79)/t43-,44-,45+,47+,48+,49-,50+,54+,55+/m0/s1

InChI key

ZVLWUMPAHCEZAW-KRNLDFAISA-N

应用

Mifamurtide 可用于免疫学和癌症相关细胞信号传导研究。

生化/生理作用

Mifamurtide 是一种免疫调节剂，可调节单核细胞和巨噬细胞的活化。Mifamurtide 上调促炎细胞因子如 TNF-α 的分泌、IL-1、IL-8、一氧化氮及前列腺素 E 2 和 D 2 。在儿童和青年高级别骨肉瘤中具有抗肿瘤作用。
Mifamurtide（胞壁酰三肽磷脂酰乙醇胺；MTP-脑磷脂；MTP-PE）是一种合成的亲脂性胞壁酰二肽类似物。它作为免疫刺激剂通过体内巨噬细胞活化促进癌细胞破坏。
胞壁酰二肽的合成亲脂性类似物。免疫刺激剂通过体内巨噬细胞活化促进癌细胞破坏。抗肿瘤免疫调节剂。

特点和优势

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单，请单击此处。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
014M4728V
113M4759V
111M4724V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A Nardin et al.
Current cancer drug targets, 6(2), 123-133 (2006-03-15)
About one third of osteosarcoma patients develop lung metastasis refractory to chemotherapy. Recent studies indicate that biological response modifiers activating the patient's immune system may help controlling minimal residual disease via pathways distinct from those used by cytotoxic drugs, and
Karthik Venkatakrishnan et al.
European journal of clinical pharmacology, 68(10), 1347-1355 (2012-03-31)
This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety/tolerability, and cardiac safety of liposomal muramyl tripeptide phosphatidyl-ethanolamine [mifamurtide (L-MTP-PE)] in healthy adults. L-MTP-PE 4 mg was administered intravenously over 30 min. Study participants were monitored from 24 h preinfusion until 72 h postinfusion. Blood
R M Durham et al.
The Journal of surgical research, 76(2), 179-184 (1998-08-12)
Muramlytripeptide phosphatidylethanolamine (MTP) stimulates synthesis of cytokines by hepatic Kupffer cells. We have shown in a perfused rat liver model that secondary ischemia/reperfusion (I/R) downregulates tumor necrosis factor alpha (TNF-alpha) expression after Escherichia coli (EC) bacteremia. Here, we tested the
N O Macková et al.
Physiological research, 51(5), 511-521 (2002-12-10)
The effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE/MLV, radioprotective immunomodulator; 10 mg/kg) and indomethacin (INDO, inhibitor of prostaglandin production; 2 mg/kg) on post-irradiation recovery of hematopoietic functions in mice were investigated. Two agents with distinct radioprotective mechanisms were administered alone
Kosei Ando et al.
Expert opinion on pharmacotherapy, 12(2), 285-292 (2011-01-14)
The standard treatment for osteosarcoma requires both macroscopic surgical wide resection and postoperative multi-drug chemotherapy in neoadjuvant and adjuvant settings. However, the 5-year event-free survival has remained at a plateau of 60-70% of patients with nonmetastatic osteosarcoma for more than
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持